文献速递消化系统肿瘤

晚期胃癌三线治疗疗效与耐受性比较:贝叶斯网络荟萃分析

Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
PubMed 文献 · Eur J Cancer · 2020-12-15

该贝叶斯网络荟萃分析纳入7项随机对照试验共2601例晚期胃癌患者,比较9种三线治疗的疗效与耐受性。结果显示纳武利尤单抗联合伊匹木单抗延长总生存最优,瑞戈非尼改善无进展生存最优,从获益风险比看纳武利尤单抗、阿帕替尼或瑞戈非尼为最佳选择。

要点

  • 纳武利尤单抗联合伊匹木单抗延长OS最优(HR 0.59)。
  • 瑞戈非尼改善PFS最优(HR 0.40),阿帕替尼次之。
  • 获益风险比最佳为纳武利尤单抗、阿帕替尼或瑞戈非尼单药。

核心结论

  • 免疫治疗(纳武利尤单抗)或抗血管生成药物(瑞戈非尼、阿帕替尼)作为三线单药与获益风险比相关。

研究设计与样本

  • 系统综述与贝叶斯网络荟萃分析,纳入7项随机对照试验共2601例患者、9种治疗。

主要发现

  • 延长OS最优为1 mg/kg纳武利尤单抗+3 mg/kg伊匹木单抗(HR 0.59,95%CrI 0.38-0.91),其次为纳武利尤单抗(HR 0.63,95%CrI 0.50-0.79)。
  • 改善PFS最优为瑞戈非尼(HR 0.40,95%CrI 0.28-0.58),其次为阿帕替尼(HR 0.45,95%CrI 0.33-0.60)。
  • 纳武利尤单抗联合伊匹木单抗与纳武利尤单抗改善ORR更优,但联合方案不良事件毒性最高。

关键数值与推荐

  • 获益风险比最佳为纳武利尤单抗、阿帕替尼或瑞戈非尼。
  • 化疗或纳武利尤单抗与伊匹木单抗两种剂量组合因耐受性差列为后续选择。

临床怎么用

  • 三线治疗选择可优先考虑纳武利尤单抗、阿帕替尼或瑞戈非尼单药以平衡获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The most effective agent for the third-line treatment of advanced/metastatic gastric cancer (AGC) has not yet been determined. The aim of this network meta-analysis is to compare the relative efficacy and tolerability of third-line treatments for AGC. MATERIALS AND METHODS: We conducted a comprehensive literature review of randomised clinical trials (RCTs) using four electronic databases. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse events (AEs) were used as efficacy or tolerability outcomes. A Bayesian network meta-analysis with a random-effects model was used. RESULTS: Seven RCTs involving 2601 patients and nine treatments were included. The results suggested that 1 mg/kg nivolumab (nivolumab1) + 3 mg/kg ipilimumab (ipilimumab3) (hazard ratio [HR] 0.59, 95% credible interval [Crl] 0.38-0.91) was the most effective treatment, followed by nivolumab (HR 0.63, 95% Crl 0.50-0.79), for prolonging OS. Regorafenib (HR 0.40, 95% Crl 0.28-0.58) was most likely to improve PFS, followed by apatinib (HR 0.45, 95% Crl 0.33-0.60). Nivolumab1 + ipilimumab3 and nivolumab were better at improving ORR, whereas nivolumab1 + ipilimumab3 had the highest toxicity based on the AEs. For benefit-risk ratio, nivolumab, apatinib or regorafenib appeared to be the best options. Chemotherapy or two different dose combinations of nivolumab and ipilimumab were ranked as the next options because of poor tolerability, despite good efficacy. CONCLUSION: Immunotherapy (nivolumab) or antiangiogenic agents (regorafenib and apatinib) are associated with benefits for benefit-risk ratio as third-line monotherapy. This study might serve as a guideline to aid in the selection of third-line treatments for AGC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Park S, Nam CM, Kim SG, et al. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. Eur J Cancer. 2020. PMID: 33338727. doi:10.1016/j.ejca.2020.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。